Biest vs Estradiol: 9 Differences Before You Switch

Best for / not for you if

Biest is not the “natural” lane and estradiol is not the “synthetic” lane. Both may be described as bioidentical. The decision is about the finished product, route, dose, evidence, and oversight — not the marketing word.

Online care is not the right starting point for every situation. Get direct clinical evaluation before starting or changing estrogen if you have new or unexplained bleeding after menopause, a personal history of an estrogen-sensitive cancer, current tamoxifen or aromatase-inhibitor use, a history of blood clots or stroke, active liver disease, or a possible pregnancy.

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

What we actually verified for this page

What we could not verify before publication:your patient-specific compounded strength, which Winona pharmacy would fill a particular prescription, your insurer’s coverage decision, your pharmacy’s live inventory, or the final amount a provider will charge after an individualized plan is selected. Those must be confirmed during intake, at checkout, with the dispensing pharmacy, or with the plan.

How we are paid: we may earn a commission if you start care with Winona, Midi Health, or Sesame Care. We earn nothing from Hone Health, AgeMD, Wells Pharmacy Network, or the over-the-counter products audited here. Read our affiliate disclosure.

Biest vs estradiol: what’s the actual difference?

Biest is a compounded combination of estriol and estradiol. Estradiol is one hormone that appears in both FDA-approved and compounded products. Sharing an estradiol component does not make the finished products equivalent: their other ingredients, strengths, delivery systems, quality controls, approved uses, and evidence can be different.

A wording correction matters here because almost every comparison page gets it wrong: “estradiol” names a hormone, not an approval status. An estradiol patch can be FDA-approved. Estradiol can also be placed in a compounded cream. The honest comparison is your exact compounded Biest prescription versus a specific, named estradiol product.

“Bioidentical” does not settle the question either. The Menopause Society uses the term for hormones with the same chemical and molecular structure as hormones produced in the body and notes that FDA-approved products can meet that description. Bioidentical does not mean compounded, safer, natural, personalized, or free of prescription requirements.

The 9 differences that actually matter

Everything else people argue about online sits downstream of these nine.

Why can’t you match the milligrams?

You cannot compare a Biest cream and an estradiol patch milligram for milligram. A cream label may report drug concentration or the amount applied; a patch reports a nominal delivery rate. Neither number, by itself, tells you that the two products create the same blood exposure, tissue exposure, symptom response, or clinical effect.

This is the question most pages dodge. Here it is properly.

There are four different quantities in this conversation, and almost everyone blends them into one:

1. Concentration— how much drug is present in a unit of product, such as mg/g or mg/mL.
2. Amount applied— concentration multiplied by the amount dispensed or used.
3. Nominal delivery— what a device is designed to release over a stated period, such as 0.05 mg per day.
4. Systemic exposure— the measured hormone exposure after absorption. This cannot be read directly from the package number.

Example:

• Biest concentration: 2.5 mg total estrogen per gram
• Amount used: 0.5 gram
• Total estrogen applied: 1.25 mg
• If the ratio is 80/20: 1.0 mg estriol + 0.25 mg estradiol applied
• Estradiol absorbed: not calculable from those label numbers
• Equivalent patch: not calculable

The cream number lives in concentration or amount-applied territory. The patch number lives in nominal-delivery territory. Setting them beside each other and choosing the bigger one is like comparing the flour in a recipe with the calories in the finished loaf.

Here is the counterintuitive part, and it is the reason this page exists: a cream can show a much larger milligram number while producing less measured estradiol exposure than a patch. The number is not lying. You are being shown a different kind of number.

The label-decoder rule

Before anyone discusses whether your prescription is “high,” “low,” or equivalent to anything else, collect these five fields exactly as written:

If the pump does not state the amount dispensed per actuation, the arithmetic stops. If the ratio order is not explicit, the arithmetic stops. If someone jumps from “mg applied” to “patch equivalent,” the arithmetic stops.

That is not caution for caution’s sake. It is the line between reading a label and inventing a prescription.

What do 80/20, 50/50, and “Biest 2.5” actually mean?

The ratio describes how the two estrogens split by weight: 80/20 usually means 80% estriol and 20% estradiol. The strength describes the total amount in a unit of product. Ratio, concentration, amount used, and frequency are set separately, so the ratio alone does not tell you your dose.

To describe what you are actually using, you need four numbers, not one:

With all four, you can calculate what was applied. You still cannot calculate absorption or an equivalent approved product.

Wells Pharmacy Network publishes the arithmetic plainly: its example of Biest 80/20 at 10 mg/g contains 8 mg estriol and 2 mg estradiol in one gram, with a stated allowable variance not exceeding plus or minus 10%. AgeMD publishes an 80/20 cream in 2.5, 4, 5, and 10 mg/g strengths. Neither company pays us. They are here because they disclose details most sellers leave until later.

A ratio by weight is not a ratio by effect

This is where the “gentle estrogen” story breaks down. If estriol is 80% of the weight, it does not follow that it creates 80% of the biological effect. Estriol and estradiol have different receptor activity, metabolism, and pharmacokinetics. No legitimate calculation turns an 80/20 weight ratio into an 80/20 clinical-effect ratio.

The one randomized Biest pharmacokinetic study also found that estriol measurements were frequently below the assay’s limit of detection. The National Academies review specifically notes assay limitations, so the study cannot be used to declare that the estriol fraction “did nothing.” It can be used to show why label composition and measured exposure are not the same thing.

The same ratio can describe very different products

The National Academies’ formulation appendix documents estradiol-and-estriol combinations in multiple forms, strengths, and units, including formulas that add progesterone or testosterone.

Two women can both say “I take Biest 80/20” and be using meaningfully different prescriptions. That is not an accusation against compounding. It is why the label in your hand — not the category name — is the beginning of the conversation.

Is Biest FDA approved?

No finished Biest product is FDA-approved, and the FDA says there are no FDA-approved drugs containing estriol in the United States. Patient-specific compounding may be lawful when the applicable federal and state requirements are met, but FDA does not review each finished compounded prescription before marketing for safety, effectiveness, or product-specific absorption.

Read that middle sentence again, because both sides of this argument abuse it.

“Not FDA-approved” does not automatically mean illegal, and it does not prove that a particular prescription harmed anyone. It means the finished compounded product did not go through FDA’s approval review. That is the distinction you need when you compare evidence, labeling, consistency, and recourse.

The current 503A framework is more specific than “all ingredients must be FDA-approved.” FDA states that a state-licensed physician or pharmacist compounding under section 503A may use bulk drug substances that meet one of the statutory routes: compliance with an applicable USP or NF monograph, use as a component of an approved drug when no applicable monograph exists, or inclusion on FDA’s 503A bulks list when the other routes do not apply. (FDA section 503A bulk-substance guidance)

What FDA says about estriol

FDA’s menopause guidance says two things without leaving room for marketing interpretation:

• there are no FDA-approved drugs containing estriol in the United States; and
• FDA does not have evidence that estriol drugs are safe and effective or safer forms of estrogen.

That is not a finding that every estriol prescription is unsafe. It is a finding that the safety and superiority claims sellers often attach to estriol have not been established to FDA’s approval standard.

The three lanes people confuse in a Biest vs estradiol search

This search pulls three materially different lanes into one conversation: FDA-approved estradiol, patient-specific compounded Biest, and nonprescription products marketed as Biest. The third lane is not a shortcut to prescription Biest. The current public records we audited are marked “unapproved drug other” and contain internally contradictory strength data.

If you take one section away from this page, make it this one.

What we found in the DailyMed records

DailyMed is the National Library of Medicine’s public label database. Its own disclaimer says labeling is submitted by companies, may not have been verified by FDA, and is not reviewed by NLM before publication. A DailyMed listing is not proof of FDA approval.

A DailyMed search returned five records carrying the name “Biest.” We audited three records updated in June 2025:

Finding one: the same record reports incompatible strengths

For the first BIEST 5.0 record, 0.4% of an 85-gram container equals 340 mg of estriol, while the structured field says 4 mg in the container — a factor of 85. The printed estradiol percentage implies 85 mg, while the structured field says 1 mg.

For the BIEST 2.5 record, 0.2% of 102 grams equals 204 mg of estriol, while the structured field says 2 mg — a factor of 102. The estradiol fields produce the same factor.

The printed percentages are internally consistent with the product names if interpreted as concentration: 0.25% total equals 2.5 mg/g, and 0.5% total equals 5 mg/g. That makes the percentage interpretation plausible. It does not verify the contents of a bottle. Only testing and an authoritative corrected label could do that.

We are not accusing anyone of substituting ingredients or misfilling a product. We are reporting a reproducible record problem: the human-readable panel and the machine-readable fields do not reconcile.

Finding two: the regulatory messages collide inside the same record

The records are classified as unapproved OTC drug labels. Their uses text refers to temporary relief from menopausal symptoms, their directions refer to use as directed by a physician, and their warnings include “for external cosmetic use only.”

Those are not interchangeable messages. A consumer should not have to decide which part of a contradictory unapproved label governs a hormone product.

Finding three: the printed numbers expose the unit trap

If the printed percentages were intended as per-gram concentrations, one gram would contain:

An FDA-approved patch may be labeled to deliver 0.025 to 0.1 mg of estradiol per day. That does notmake one gram of either cream “five to forty patches.” The cream figure is applied drug; the patch figure is nominal daily delivery. The comparison proves why larger-looking numbers cannot be converted — not that one product creates more blood exposure.

How to check a product yourself in about a minute

1. Search DailyMed for the exact product name or NDC.
2. Read the marketing status. “Unapproved drug other” is not FDA approval.
3. Compare the Drug Facts percentage with the structured ingredient amount and package quantity.
4. Confirm the same information on the physical package.
5. For a prescription compound, ask the prescriber and dispensing pharmacy for the exact formula, unit, amount per actuation, beyond-use date, and pharmacy name in writing.
6. Do not use a public label record to decide your dose or to change treatment.

This is the original evidence block on this page. Anyone can reproduce it from the linked records. That is the standard: not “trust us,” but “open the same source and check our arithmetic.”

Does Biest cream deliver as much estrogen as an estradiol patch?

The direct evidence does not support a simple yes. In one 40-woman pharmacokinetic trial, the two lower Biest 80/20 strengths produced substantially lower estradiol exposure than a 0.05 mg/day patch; the highest tested strength was not statistically different. That is not a conversion chart and does not establish symptom or safety equivalence.

Two studies matter here, but they do not study the same product. The 2013 trial is direct Biest evidence. The 2023 cohort studied compounded estradiolcream rather than Biest, so it is adjacent evidence about compounded transdermal absorption — not a second Biest trial.

The randomized Biest trial

Sood and colleagues published a randomized, blinded, four-arm pharmacokinetic trial in Maturitas in 2013. Forty postmenopausal women received one of three compounded Biest 80/20 cream strengths plus compounded oral progesterone, or a Vivelle-Dot 0.05 mg/day estradiol patch plus Prometrium 100 mg. The treatment period was 16 days.

AUC — area under the concentration-time curve — is a measure of total exposure over the measured period. The values above are the study’s reported comparisons, not dose equivalents.

The lower Biest strengths produced markedly lower estradiol exposure than the patch despite larger-looking applied milligram numbers. The highest strength did not show a statistically significant difference from its patch comparison, but a small trial that fails to show a difference does not prove equivalence.

The study also reported substantial variation in serum concentrations with the cream. Estriol measurements were frequently below the assay’s limit of detection, which the National Academies later identified as an interpretation problem. You cannot turn those findings into “estriol was inactive,” and you cannot turn the 3.0 mg arm into a switching rule.

The larger estradiol-cream cohort

Newman and colleagues published a retrospective cohort in Menopausein 2023. It included 8,720 untreated postmenopausal women, 1,062 treated women — 777 using patches, 132 using gels, and 153 using compounded estradiol creams — and 16,308 premenopausal women.

The outcome was urinary estrogen exposure, not symptom relief and not a direct Biest comparison. The compounded estradiol-cream group had lower exposure than the FDA-approved patch and gel groups, although exposure increased with higher cream doses.

That supports one narrow conclusion: compounded transdermal cream dosing cannot be assumed to produce the same exposure as an approved patch or gel. It does not tell you what your Biest prescription will do.

What these studies do not show

• a validated Biest-to-patch conversion;
• equal symptom relief at any paired doses;
• long-term safety equivalence;
• an ideal ratio;
• that a cream “failed” because one laboratory value is low;
• that a woman doing well on a cream should stop it abruptly.

Sood was small, short, and used one compounded formulation. Newman was retrospective and studied compounded estradiol cream, not estriol-plus-estradiol Biest. Both are useful precisely because their limits are visible.

If Biest is working for you, this evidence is not a command to stop.It is permission to ask a better question. If symptoms are still breaking through, “estrogen does not work for me” may be the wrong conclusion. “What exactly am I applying, how much am I absorbing, and is the route matched to the symptom?” is the conversation worth having.

Is estriol safer or gentler than estradiol?

Estriol is commonly described as a weaker or “gentler” estrogen, but gentler has not been shown to mean safer. FDA says it does not have evidence that estriol drugs are safe and effective or safer forms of estrogen. One large long-term human signal often omitted from marketing comes from oral estriol — not transdermal Biest — and it points in the opposite direction.

This is the claim Biest is sold on. It deserves the real evidence, not a slogan.

Weiderpass and colleagues published a Swedish population-based case-control study in The Lancet in 1999. It compared 789 women with endometrial cancer with 3,368 controls aged 50 to 74.

Now the honest limits, because they matter. This was an observational case-control study of oral estriol, mostly 1 to 2 mg, in Sweden in the 1990s. It was not a trial of transdermal Biest cream. The vaginal route did not show the same association. The study cannot prove that a transdermal Biest prescription causes endometrial cancer.

What it does destroy is the blanket claim that estriol is “too weak to matter.” Potency language is not a safety outcome. A lower receptor potency does not erase dose, route, duration, tissue exposure, or uterine-lining risk.

On breast outcomes, the answer is less satisfying and more important: no robust randomized clinical-outcome trial has shown that a compounded estriol-and-estradiol mixture is safer for the breast than an FDA-approved estradiol product. Anyone selling that conclusion is moving beyond the evidence.

What changed on FDA hormone labels in 2026?

On February 12, 2026, FDA announced the first six menopause hormone products with approved labeling changes from its class-wide initiative. The changes removed certain boxed-warning language about cardiovascular disease, breast cancer, and probable dementia from those products. The boxed warning about endometrial cancer remains for systemic estrogen-alone products, and FDA said it was continuing to work with manufacturers on other products. (FDA 2026 labeling update)

That update applies to FDA-approved products with standardized prescribing information. It does not convert a compounded product into an approved one, prove estriol safer, or create a Biest conversion.

If you have a uterus, what is protecting your lining?

If you use systemic estrogen and still have a uterus, you need an adequate endometrial-protection plan unless your regimen provides protection another way. The British Menopause Society’s May 2026 guidance says compounded transdermal progesterone creams and gels have variable absorption and may not provide sufficient protection. Settle this before you pay.

Plain version: unopposed systemic estrogen can stimulate the endometrium. Adequate progestogen exposure is commonly used to reduce the risk of endometrial hyperplasia and cancer. The dose, route, schedule, and estrogen dose all matter.

The British Menopause Society’s current clinician tool says transdermal micronized progesterone has variable absorption and is unlikely to provide sufficient estrogen opposition. It specifically concludes that transdermal micronized progesterone should not be used for endometrial protection in HRT regimens based on current evidence.

This matters because a combination cream can make the lining plan feel “handled” simply because progesterone appears on the label. That is not the same as demonstrating adequate endometrial exposure.

Write this sentence down and use it exactly:

“I have a uterus. If I use this systemic estrogen, what specifically is protecting my uterine lining, at what dose and schedule, and how will unexpected bleeding be evaluated?”

A good prescriber will not be offended by that question. A clear answer is part of the prescription.

If you have had a hysterectomy, the answer may be different, especially if the hysterectomy was subtotal or related to severe endometriosis. If you use low-dose vaginal estrogen only for genitourinary symptoms, routine progestogen is generally not recommended in the same way because systemic exposure is low; that is a different treatment lane. Read our vaginal estrogen guide before mixing local and systemic rules.

New bleeding after menopause is not a normal “adjustment” to troubleshoot from an article. It needs prompt clinical evaluation.

What do ACOG, the National Academies, and The Menopause Society say?

The major guidance is aligned: do not use compounded bioidentical menopausal hormone therapy routinely when an FDA-approved formulation can meet the need. The National Academies names the clearest exceptions — a documented allergy to an ingredient in approved products or a documented need for a dosage form that approved products do not provide.

Most pages either hide this or weaponize it. Here it is with the useful part intact.

The other side, stated fairly

Compounding exists because approved products do not solve every real-world problem. A patient can have a documented reaction to an adhesive, dye, filler, or base. A needed dosage form may not exist. A clinician may need a patient-specific formulation after standard options have been tried or ruled out.

That is not the same as saying compounded treatment is routinely safer, more natural, or more effective. The honest case for compounding is a specific need, not a halo around the word “custom.”

The phrase your clinician is reacting to

If a clinician has been short with you about a compounded prescription, the issue may be the gap between “I prefer custom” and “the approved choices do not meet this documented need.” Those are different clinical conversations.

You do not need to apologize for asking. Bring the reason into focus:

• “I had a documented reaction to the patch adhesive.”
• “I cannot use the available oral excipients.”
• “The approved products do not provide the dosage form I need.”
• “I am already stable on this prescription and want a documented review of its formula and monitoring.”

That turns a vague brand argument into a decision a clinician can actually evaluate.

Which route matches what you are actually treating?

Route should follow the symptom, not the marketing word. Systemic products — patches, gels, sprays, and tablets — treat whole-body symptoms such as hot flashes and night sweats. Low-dose vaginal products treat local symptoms such as dryness, burning, and pain with sex. A Biest cream may be intended for systemic or local use, so the written prescription and directions control.

This is where money gets wasted and symptoms do not improve — not because “hormones failed,” but because the product was aimed at the wrong target.

The quickest self-check:

• If your only complaint is vaginal or vulvar dryness, irritation, urinary symptoms, or pain with sex, ask whether a targeted vaginal product is the cleaner route.
• If the problem is hot flashes or night sweats, you are discussing systemic treatment.
• If you have both, a clinician may use systemic treatment and add local therapy if local symptoms remain. Needing both is not a treatment failure.

Do not put a body cream in or around the vagina unless the prescription and clinician specifically direct that use. Do not assume a vaginal product belongs on the arms, thighs, or abdomen. Route is part of the dose.

What does Biest cost compared with FDA-approved estradiol?

The answer depends on whether you are comparing medication alone with an all-in telehealth program. Winona’s compounded Biest cream is currently listed from $89 per 28-day supply — about $1,160 across 365 days. Its FDA-approved estradiol patch is listed from $149 per 28-day supply — about $1,942 before any separately prescribed progesterone.

Most cost pages quote a monthly sticker and stop. That hides the billing interval, the visit model, and whether medication is included.

Prices and terms verified September 1, 2026 on the companies’ own pages. Treatment, dose, and medication are never guaranteed. Published “from” prices are not quotes for your prescription. Winona’s annual figures use 365 ÷ 28 = 13.04 billing cycles. AgeMD says its displayed monthly rates are paid as one upfront term payment. Hone’s total combines the page’s $80 medication price with the Premium tier it assigns to Biest.

What this table actually proves

First: compounded is not automatically cheaper, and FDA-approved is not automatically more expensive. Within Winona, the compounded cream currently has the lower published cash price. At a retail pharmacy, a generic approved product may cost less or more depending on the exact NDC, quantity, plan, deductible, coupon rules, and pharmacy.

Second: a telehealth-program price and a pharmacy price are not the same kind of number. One may bundle clinical access and shipping. The other may be medication only. Price the whole path:

consult or subscription + labs + medication + progesterone if needed + shipping + refill cadence

Third: billing every 28 days is not monthly billing. Twelve calendar months contain about 13.04 28-day cycles. That is why a published $89 charge is about $1,160 a year, not $1,068.

There is no single primary-source national cash price for generic estradiol. Your defensible number is the live quote from your pharmacy or plan for the exact product, quantity, and date.

Does insurance, Medicare, HSA, or FSA cover Biest?

Compounded Biest coverage is plan-specific and is usually less straightforward than coverage for a named FDA-approved estradiol product. Medicare Part D does not treat a compound as one automatically covered drug: CMS says coverage is assessed at the eligible-ingredient level. HSA or FSA card acceptance is not a final coverage or tax ruling.

Four distinctions save real money.

1. The visit and the medication are separate claims

A clinic can be in-network while the prescription is not on your formulary. Always ask about both sides:

• Is the clinician or medical group in-network?
• Is the exact drug name, strength, quantity, and NDC on the plan formulary?
• Is prior authorization required?
• Does the plan require a preferred pharmacy or mail order?

2. Medicare Part D compound coverage is ingredient-specific

CMS’s Part D manual says compounded products as a whole do not automatically satisfy the definition of a Part D drug. A plan may cover eligible Part D ingredients in the compound, while non-Part-D ingredients and other costs may not be covered. (CMS Part D manual, Chapter 6)

3. A card being accepted is not the same as an expense being adjudicated

IRS guidance includes prescribed medicines among medical expenses that may qualify, but HSA and FSA administration still depends on the account, documentation, and applicable tax rules. Keep the prescription and itemized receipt. (IRS Publication 502)

4. Provider rules can create a hard stop even when you intend to self-pay

• Winona: cash-pay; says it does not bill insurance directly; accepts HSA/FSA cards and provides documentation for possible reimbursement.
• Midi Health: says it is in-network with most PPO plans; self-pay is $250 for the first visit and $150 for returns. Medicare is out of network; Medicare beneficiaries may self-pay but cannot submit claims related to Midi care. Midi says it cannot accept Medicaid or Medi-Cal patients, even as self-pay.
• Sesame Care: does not bill insurance for the subscription, and its current terms require users to certify they are not Medicare, Medicaid, or TRICARE beneficiaries.

If insurance is the difference between starting and not starting, begin with the exact approved product and your exact plan — not the category word “HRT.”

Who prescribes Biest online, and what do they disclose before you pay?

The most useful column is not the logo. It is whether the company publishes the ratio, exact strength, billing commitment, pharmacy path, and FDA status before your card is charged.

Provider-stated facts verified September 1, 2026. “FDA-registered pharmacy” is not FDA approval of the finished drug. A state-licensed 503A pharmacy and an FDA-registered 503B outsourcing facility are different categories; ask which category applies to the medication you would receive.

The correction we owe you about a company we may earn from

Winona’s current Estrogen Body Cream page says: “The active ingredients in your Estrogen Body Cream, estradiol and estriol, are FDA approved.” Its FAQ also says its 503A compounded medications use FDA-approved ingredients.

That is not correct as written. FDA says there are no FDA-approved drugs containing estriolin the United States. And section 503A does not reduce to “every bulk ingredient must be FDA-approved”; FDA’s current criteria also include applicable USP or NF monographs and the 503A bulks framework.

This is not a semantic gotcha. The sentence appears directly under the question “Is Estrogen Body Cream FDA approved?” A reasonable reader could leave with the impression that estriol has FDA approval when it does not.

Now the part we are not going to flatten: Winona still has real strengths. It publishes a clear 50/50 ratio, a current $89 price, an ingredients list, a 28-day refill cycle, a 24-hour cancellation window after order processing starts, and a specific HRT age range of 35 to 59. It says physician messaging, shipping, and dose adjustments are included. It offers both compounded cream and FDA-approved estradiol patches and tablets, which lets a clinician keep you inside one care model while changing regulatory lanes.

It also has real limits. The exact compounded strength is not visible on the public product page. It is cash-pay. HRT service is limited to 37 states plus Puerto Rico, and it does not treat women 60 or older through its HRT program. Once an order moves past the 24-hour processing window, the FAQ says it cannot be cancelled, refunded, or returned.

Both things are true: the service is unusually transparent on price and logistics, and its FDA sentence needs correction.

The four questions to ask any Biest seller before you pay

1. What is the complete written formula? Ask for every active ingredient, ratio, concentration, amount per actuation, route, frequency, and quantity dispensed.
2. Who compounds it, under what category? Ask for the pharmacy name, state license, and whether it operates as a traditional 503A pharmacy or an FDA-registered 503B outsourcing facility for the relevant product.
3. What is the uterine-lining plan? If you have a uterus and the estrogen is systemic, ask which progestogen, route, dose, schedule, and bleeding follow-up apply.
4. When does the money become nonrefundable? Ask for the first processing date, refill cadence, cancellation deadline, commitment, and whether a dose change triggers another charge.

A provider who can answer those four questions has earned the next step. A provider who changes the subject has answered too.

What are the FDA-approved estradiol routes instead?

FDA-approved estradiol is not one product. The main routes are patch, gel or spray, oral tablet, and vaginal cream, insert, or ring. The right alternative to a compounded cream depends on whether you need systemic or local treatment, your uterus status, your history, adhesive tolerance, insurance, and pharmacy availability.

The estradiol patch dosage guide explains why patch delivery rates cannot be used as Biest equivalents. The vaginal estrogen guide keeps local treatment separate from systemic treatment.

Medication availability can change by manufacturer, strength, pharmacy, and week. Check the FDA database, your pharmacy, and our dated estradiol patch shortage tracker for the exact product rather than treating the whole category as unavailable.

Three current online-care paths

How do you switch from Biest to estradiol without guessing?

Do not convert the numbers yourself and do not create a gap or overlap on your own. A safe switch starts with the exact current formula, a written stop/start plan, a uterine-lining plan when relevant, pharmacy-stock confirmation, and a scheduled follow-up. The prescription — not an online calculator — sets the new product and dose.

Bring these numbers with you:

What not to do

• Do not equate a total Biest milligram number with a patch delivery rate.
• Do not stop a progestogen because the new estrogen number looks smaller.
• Do not apply two products together, overlap them, taper them, or leave a treatment gap unless the written plan says to.
• Do not cut a patch unless that specific product’s labeling or your prescriber permits it.
• Do not use a vaginal product as a systemic substitute or a body cream as a vaginal product without direct instructions.
• Do not diagnose absorption failure from symptoms or one consumer lab value.
• Do not let a refill ship while you are still deciding whether to change.

The money-saving housekeeping step

“Cancel anytime” is not “refund anytime.” Before the switch, screenshot the next processing date and the written cancellation rule. Winona’s current FAQ allows a full refund only within its 24-hour processing window; after that, the order cannot be cancelled, refunded, or returned. AgeMD’s lowest displayed monthly rate requires an annual upfront payment. Sesame does not refund the first month after the initial visit occurs and requires cancellation before the next billing cycle to prevent future charges.

When to get help sooner

Do not wait for a routine follow-up for chest pain, shortness of breath, one-sided leg swelling, sudden new neurologic symptoms, or a sudden severe headache — seek urgent or emergency assessment. New postmenopausal bleeding needs prompt clinical evaluation. For nonurgent side effects or poor symptom control, use the prescriber’s contact route and scheduled review rather than changing the dose yourself.

If your current clinician cannot explain your ingredients, route, uterine-lining plan, or monitoring, the next step is not a random different cream. It is a clinician who can.

How we researched this page

This page applies The HRT Index Verification Standard. We verify five pillars in this order: clinical legitimacy, care quality, medication fit, price transparency, access. We do not publish invented provider scores because one number would hide the trade-offs this page exists to expose.

What we did

• Read FDA’s current menopause and compounding pages, including the May 2026 section 503A bulk-substance criteria and February 2026 label-update announcement.
• Searched DailyMed for “Biest,” opened the public records, compared the Drug Facts percentages with the structured ingredient fields and package quantities, and reproduced the arithmetic shown above.
• Read current public product, FAQ, state, price, refund, billing, insurance, and pharmacy disclosures from Winona, AgeMD, Hone Health, Wells Pharmacy Network, Midi Health, and Sesame Care.
• Read the current positions of ACOG, The Menopause Society, the National Academies, the Endocrine Society, and the British Menopause Society.
• Read the original abstracts and evidence review for the Sood, Newman, and Weiderpass studies.
• Checked every internal link used on this page.

What we did not do

• We did not test a cream, assay a bottle, inspect a pharmacy, or verify a patient’s prescription.
• We did not interview a clinician for this page.
• We did not infer a patient-specific strength from a product name.
• We did not publish live review scores or testimonials.
• We did not turn one study into a conversion chart.
• We did not label this page medically reviewed.

Provider prices and policies are provider-stated unless the table explicitly says otherwise. Regulatory and medical claims come from primary sources. Original calculations are labeled as The HRT Index arithmetic and can be reproduced from the linked source data.

This page is editorial research and has not been medically reviewed by a clinician. See our medical review policy. If you find a factual error, email partners@thehrtindex.com and see our corrections policy.

Frequently asked questions

Is Biest the same as estradiol?

No. Biest is a compounded combination of estriol and estradiol. Estradiol is one hormone available in both FDA-approved and compounded products. Both can contain estradiol, but the finished products are not equivalent in formula, strength, route, approval status, or evidence.

Is Biest FDA approved?

No. There is no FDA-approved finished Biest product, and FDA says there are no FDA-approved drugs containing estriol in the United States. A patient-specific prescription may be lawfully compounded when the applicable requirements are met, but the finished compound is not FDA-approved.

Is estradiol FDA approved?

Specific estradiol products are FDA-approved, including patches, gels, sprays, tablets, and vaginal products. Estradiol can also be compounded, so the ingredient name alone does not establish approval. Check the exact product and labeling.

What does Biest 80/20 mean?

It usually means 80% of the total estrogen weight is estriol and 20% is estradiol. It tells you the split, not the total dose. You still need the concentration, amount used, frequency, route, and confirmation of which ingredient is listed first.

Is 50/50 Biest stronger than 80/20?

At the same total concentration and amount applied, 50/50 contains 2.5 times as much estradiol by weight as 80/20 because the estradiol fraction is 50% instead of 20%. That does not prove 2.5 times the absorption, symptom effect, or risk. Stronger cannot be answered from the ratio alone.

What does "Biest 2.5" mean?

It often refers to 2.5 mg of total estrogen in a specified amount of product, commonly one gram, but naming conventions are not a substitute for the written prescription. Confirm the unit. "2.5 mg/g," "2.5 mg per click," and "2.5 mg per capsule" are different prescriptions.

What estradiol patch equals Biest 2.5 mg?

There is no validated equivalent. A Biest number may describe total estrogen applied, while a patch number describes nominal estradiol delivery per day. The direct pharmacokinetic study does not establish a conversion.

Can I switch from Biest cream to an estradiol patch?

A prescriber can switch a patient when appropriate, but the starting patch cannot be calculated by matching the printed numbers. Bring the full formula, amount used, route, symptom response, uterus status, and uterine-lining plan. Get written instructions for when to stop one product and start the other.

Is Biest safer than estradiol?

There is no robust clinical-outcome evidence showing that compounded Biest is safer than an FDA-approved estradiol product. FDA says it does not have evidence that estriol drugs are safer forms of estrogen. Route, dose, age, timing, history, uterus status, and progestogen exposure all matter.

Is estriol weaker than estradiol?

Estriol is often described as a lower-potency estrogen, but that does not create a universal dose or safety conversion. The clinical result still depends on amount, route, exposure, duration, and tissue. "Weaker" does not mean harmless.

Is Biest more natural than estradiol?

No useful treatment decision follows from that claim. Estradiol in an FDA-approved product can be chemically identical to endogenous estradiol. "Bioidentical" describes molecular structure; it does not mean compounded, plant-like, safer, or better absorbed.

Does Biest contain progesterone?

Biest usually refers to estriol plus estradiol. Some custom products add progesterone, testosterone, or another hormone. Read every active ingredient. The word Biest does not tell you the complete formula.

Do I need progesterone with Biest?

If the Biest is intended to provide systemic estrogen and you still have a uterus, an adequate endometrial-protection plan is generally needed. Do not assume progesterone in the same transdermal cream is sufficient; current British Menopause Society guidance says transdermal micronized progesterone is unlikely to provide adequate protection.

Does Biest contain testosterone, and is it controlled?

Biest itself refers to estriol and estradiol, but a custom prescription may add testosterone. Testosterone is a Schedule III controlled substance in the United States. It requires a valid prescription and should never be treated as a casual, guaranteed, or over-the-counter add-on.

Is Biest cream local or systemic?

The dosage form does not answer the question. Check the concentration, amount, application site, frequency, and prescriber's stated goal. A body cream may be intended for systemic absorption; a separately prescribed vaginal preparation may be intended for local treatment.

Can I put Biest cream on the vulva or inside the vagina?

Only if the written prescription and clinician specifically direct that route. A body cream, vaginal cream, and vulvar application are not interchangeable. Do not improvise a new application site because symptoms are local.

Is vaginal estradiol the same as Biest cream?

No. Low-dose vaginal estradiol is a named local-treatment category for genitourinary symptoms and typically creates much lower systemic exposure than systemic therapy. A Biest body cream is a different prescription with a different formula and target unless its instructions explicitly say otherwise.

Can I buy Biest without a prescription?

Retail products marketed as Biest are sold without a prescription. We do not recommend treating them as substitutes for a patient-specific prescription. The DailyMed records audited on this page are marked "unapproved drug other" and contain strength fields that do not reconcile.

Does insurance cover Biest?

Sometimes, but coverage is inconsistent and often ingredient-specific. A plan may cover none, some eligible components, or a separate FDA-approved alternative. Ask the plan about the exact formula, dispensing pharmacy, NDC or billing code, and compounding fee. Do not rely on the seller's HSA/FSA badge as proof of insurance coverage.

Does Medicare Part D cover Biest?

Not as one automatically covered finished product. CMS says Part D coverage for compounds is evaluated at the eligible-ingredient level. A plan may cover qualifying Part D ingredients while excluding non-Part-D ingredients and other charges. Ask the plan to run the exact prescription.

Can I use HSA or FSA funds for Biest?

A prescribed medicine may qualify as a medical expense under applicable rules, but account administration and documentation still matter. Keep the prescription and itemized receipt. A merchant's ability to process the card is not a final eligibility determination.

Why would a clinician prescribe Biest?

The clearest evidence-based reasons are a documented allergy or reaction to ingredients in available approved products, or a documented need for a dosage form that approved products do not provide. A clinician may also continue an established patient-specific regimen after reviewing its formula, response, risks, and alternatives.

Did FDA remove all estrogen warnings in 2026?

No. FDA approved targeted labeling changes for the first six menopause hormone products in February 2026. Certain boxed-warning language was removed, but the endometrial-cancer warning remains for systemic estrogen-alone products. The changes do not apply to compounded products as if they were approved labels.

Can a blood or saliva test tell me my equivalent dose?

No consumer test can turn a Biest dose into a patch equivalent. Hormone levels can be useful for specific clinical questions, but routine testing is not a validated conversion method. A prescriber should use the exact prescription, symptom target, history, and response, not a home arithmetic target.

What should I bring to my appointment?

Bring a photo of the complete label and dispenser, the pharmacy name, every active ingredient, the ratio, concentration, amount per pump or click, amount used, frequency, application site, uterus status, progestogen plan, symptoms that improved, symptoms that remain, side effects, insurance information, and your next refill-processing date.